Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael H. Tomasson, Eli Gabayan, Syed Abbas Ali, Gabriel Afram, Sona Ghorashi, Trish Creel, Luisa Paccagnella, Carolyn Lou, Ola Landgren

Blood (2024) 144 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2024-210520

Published: 2024

Journal Articles

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Blood (2022) 140 (Supplement 1): 391–393.

https://doi.org/10.1182/blood-2022-162440

Published: 2022

Journal Articles

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar Jacques Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Yair Levy, Michael H Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P Chu, Cristina J. Gasparetto, Andrew P. Dalovisio, Michael Sebag, Alexander M Lesokhin

Blood (2022) 140 (Supplement 1): 388–390.

https://doi.org/10.1182/blood-2022-166494

Published: 2022

Journal Articles

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Blood (2021) 138 (Supplement 1): 895.

https://doi.org/10.1182/blood-2021-150519

Published: 2021

Journal Articles

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

James E Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Michael H. Tomasson, Christopher A. Yasenchak, Damian J. Green, Hong Li, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2021) 138 (Supplement 1): 2740.

https://doi.org/10.1182/blood-2021-146047

Published: 2021

Journal Articles

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Mark A Fiala, BS, CCRP, Jesse Keller, MD, Jeevan Sekhar, MD, Connie Ceriotti, RN, BSN, Camille N. Abboud, MD, John F DiPersio, MD PhD, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Keith Stockerl-Goldstein, Ravi Vij, MD MBA

Blood (2016) 128 (22): 3329.

https://doi.org/10.1182/blood.V128.22.3329.3329

Published: 2016

Journal Articles

HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)

Blood (2016) 128 (22): 3250.

https://doi.org/10.1182/blood.V128.22.3250.3250

Published: 2016

Journal Articles

Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

Mark A Fiala, BS, CCRP, James Dukeman, BS, Keith Stockerl-Goldstein, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Daniel Auclair, PhD, Ravi Vij, MD MBA

Blood (2016) 128 (22): 2349.

https://doi.org/10.1182/blood.V128.22.2349.2349

Published: 2016

Journal Articles

The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

Mark A Fiala, BS, CCRP, James Dukeman, BS, Keith Stockerl-Goldstein, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Ravi Vij, MD MBA

Blood (2016) 128 (22): 2350.

https://doi.org/10.1182/blood.V128.22.2350.2350

Published: 2016

Journal Articles

Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors

Chantiya Chanswangphuwana, MD, Michael P. Rettig, PhD, Walter Akers, Deep Hathi, Matthew Holt, Julie O'Neal, PhD, Julie Ritchey, Danny Kohnen, Justin A King, Michael H. Tomasson, MD, Ravi Vij, MD, Monica Shokeen, PhD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 2056.

https://doi.org/10.1182/blood.V128.22.2056.2056

Published: 2016

Journal Articles

Uncovering Clonal and Subclonal Druggable Targets in Multiple Myeloma Using Omic Data

Adam David Scott, PhD, Venkata D Yellapantula, PhD, Christopher J Yoon, BS, Michael Wendl, PhD, Michael H. Tomasson, MD, Mark A Fiala, BS, CCRP, John F. DiPersio, MD, PhD, Ravi Vij, MD, Li Ding, PhD

Blood (2016) 128 (22): 2084.

https://doi.org/10.1182/blood.V128.22.2084.2084

Published: 2016

Journal Articles

Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status

Mark A. Fiala, BS, CCRP, Jesse Keller, MD, Keith E. Stockerl-Goldstein, MD, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD, Tanya M Wildes, MD MSCI

Blood (2014) 124 (21): 555.

https://doi.org/10.1182/blood.V124.21.555.555

Published: 2014

Journal Articles

Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients

Mark A. Fiala, BS, CCRP, Jesse Keller, MD, Keith E. Stockerl-Goldstein, MD, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD, Tanya M Wildes, MD MSCI

Blood (2014) 124 (21): 5696.

https://doi.org/10.1182/blood.V124.21.5696.5696

Published: 2014

Journal Articles

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Jesse Keller, MD, Mark A Fiala, BS, CCRP, Jeevan Sekhar, Connie Ceriotti, Melissa Allen, Camille N. Abboud, MD, Keith E. Stockerl-Goldstein, MD, Tanya M Wildes, MD MSCI, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 4731.

https://doi.org/10.1182/blood.V124.21.4731.4731

Published: 2014

Journal Articles

Inherited Loss of Samsn1 Contributes to Increased Risk of MGUS and MM through Effects on Multiple Cell Types, Including B-Cells, Transformed Myeloma Cells, and Macrophages

Sarah Amend, PhD, William C Wilson, PhD, Liang Chu, PhD, Daniel Serie, PhD, Celine M Vachon, PhD, Lan Lu, MSci, Xinming Su, PhD, Michelle A Hurchla, Dingyan Wang, PhD, Pengyuan Liu, PhD, Ravi Vij, MD, Graham A Colditz, MD, Dr.PH., Katherine N Weilbaecher, MD, Michael H. Tomasson, MD

Blood (2014) 124 (21): 2075.

https://doi.org/10.1182/blood.V124.21.2075.2075

Published: 2014

Journal Articles

Genetic Susceptibility Markers of Multiple Myeloma in African-Americans

Kristin A Rand, PhD, M.P.H., Chi Song, M.S., Amie E. Hwang, PhD, M.P.H., Carol A. Huff, MD, Leon Bernal-Mizrachi, MD, Michael H Tomasson, MD, Sikander Ailawadhi, MD, David J. Van Den Berg, PhD, Xin Sheng, PhD, John J. Graff, PhD, M.S., David V. Conti, PhD, Todd Zimmerman, MD, Edward Peters, D.MD S.M, Sc.D., Seema Singhal, MD, Cathryn H. Bock, PhD, Karen Pawlish, M.P.H., Graham A Colditz, MD, Dr.PH., Xin Sheng, PhD, Alexander Stram, M.S., Sara S. Strom, PhD, Benjamin Rybicki, PhD, Rick Kittles, PhD, Howard Terebelo, DO, Janet Stanford, PhD, MPH, Phyllis J. Goodman, PhD, Sonja I Berndt, PhD, John Carpten, PhD, Anselm JM Hennis, MSc,PhD MRCP, FRCP, Lisa Chu, PhD, M.P.H., Graham Casey, PhD, W R Driver, MSPH, Eric A. Klein, MD, M. Christina Leske, MD MPH, Esther John, PhD, Adam Bryant Murphy, MD, Christine Neslund-Dudas, PhD, Victoria L. Stevens, PhD, Curtis Pettaway, MD, Wei Zheng, MD PhD MPH, Suh-Yuh Wu, M.A., John Witte, PhD, Siqun Lilly Zheng, MD, Jianfeng Xu, MD,Dr.PH, Nikhil C. Munshi, MD, Ann Hsing, PhD, Sue Ingles, PhD, Jayesh Mehta, MD, Lisa B. Signorello, PhD, Stephen Jacob Chanock, MD, Barbara Nemesure, PhD, Ann M Mohrbacher, MD, Nalini Janakiraman, MD, William J Blot, MD, Brian E. Henderson, MD, Laurence N. Kolonel, MD PhD, Kenneth C. Anderson, MD, Brian C-H Chiu, PhD, Jeffrey Zonder, MD, Robert Z. Orlowski, PhD MD, Sagar Lonial, MD, Daniel O. Stram, PhD, Christopher Haiman, Sc.D., Wendy Cozen, DO, MPH

Blood (2014) 124 (21): 2030.

https://doi.org/10.1182/blood.V124.21.2030.2030

Published: 2014

Journal Articles

Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans

Blood (2013) 122 (21): 1872.

https://doi.org/10.1182/blood.V122.21.1872.1872

Published: 2013

Journal Articles

Preclinical Development Of a Nanomedicne Approach For Multiple Myeloma Targeting The Myc Oncoprotein

Deepti Soodgupta, PhD, Dipanjan Pan, PhD, Grace Hu, MS, Angana Senpan, PhD, Xiaoxia Yang, BS, Katherine N Weilbaecher, MD, Edward V. Prochownik, MD, PhD, Gregory M Lanza, MD, PhD, Michael H Tomasson, MD

Blood (2013) 122 (21): 4228.

https://doi.org/10.1182/blood.V122.21.4228.4228

Published: 2013

Journal Articles

Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma

Kristen M. Sanfilippo, MD, Brian F Gage, MD, MSc, Suhong Luo, MPH, Ravi Vij, MD, Michael H. Tomasson, MD, Katherine N Weilbaecher, MD, Kenneth R. Carson, MD

Blood (2013) 122 (21): 3182.

https://doi.org/10.1182/blood.V122.21.3182.3182

Published: 2013

Journal Articles

A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1

Kristin A Rand, Ph.D., M.P.H., Nicola Camp, PhD, Alessandro Martino, Ph.D., Eric W. Dean, MD, Daniel J. Serie, Ph.D., Christopher K. Edlund, M.S., Donglei Hu, M.S., Karen Curtin, Ph.D., Scott Huntsman, MS, David J. Van Den Berg, Ph.D., Anneclaire De Roos, PhD, Elizabeth E Brown, Ph.D., Graham G. Giles, Ph.D., John J. Spinelli, Ph.D., Sikander Ailawadhi, M.D., Brenda M. Birmann, ScD, Angela R Brooks-Wilson, Ph.D., Richard K Severson, PhD, Paige M Bracci, PhD, Mulugeta Gebregziabher, PhD, Michael H. Tomasson, MD, Ann M. Mohrbacher, MD, Guido J. Tricot, M.D., Ph.D., Daniele Campa, M.D., Ph.D., Thomas Martin, III, M.D., Brian E. Henderson, M.D., Maurizio Zangari, MD, Nathaniel Rothman, MD, MPH, MHS, Stephen Jacob Chanock, MD, Shaji Kumar, MD, Laurence N. Kolonel, MD, PhD, Jeffrey Lee Wolf, MD, Graham A Colditz, M.D., Dr.PH., S. Vincent Rajkumar, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Christopher Haiman, Sc.D., David V. Conti, Ph.D., Federico Canzian, PhD, Celine M Vachon, PhD, Elad Ziv, MD, Wendy Cozen, D.O., M.P.H.

Blood (2013) 122 (21): 3111.

https://doi.org/10.1182/blood.V122.21.3111.3111

Published: 2013

NARROW

Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)

Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors

Uncovering Clonal and Subclonal Druggable Targets in Multiple Myeloma Using Omic Data

Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status

Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Inherited Loss of Samsn1 Contributes to Increased Risk of MGUS and MM through Effects on Multiple Cell Types, Including B-Cells, Transformed Myeloma Cells, and Macrophages

Genetic Susceptibility Markers of Multiple Myeloma in African-Americans

Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans

Preclinical Development Of a Nanomedicne Approach For Multiple Myeloma Targeting The Myc Oncoprotein

Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma

A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only